Gedeon Richter signs licence and supply deal with Pantarhei Bioscience

…wake of the product launch. Gedeon Richter is responsible for the funding of all expenses associated with the required clinical and post approval studies. According to Zsuzsa Beke, the head of PR for the company, the product may be launched in 2026, and annual revenues of €50m are expected.

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.